Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best small cap AI stocks to buy according to analysts. On July 8, ...

You should probably be saving more, but even if you can't do that, you can get more out of the money you are able to save.

Recursion's AI-designed cancer drugs REC-3565 and REC-617 show early clinical promise, with one patient responding ...

In spite of this underperformance, the clinical-stage TechBio firm continues to attract interest for its innovative approach ...

AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school giants.

Bullish option flow detected in Recursion Pharmaceuticals (RXRX) with 25,074 calls trading, 1.6x expected, and implied vol increasing almost 21 ...

In the latest close session, Recursion Pharmaceuticals (RXRX) was down 1.68% at $6.43. This change lagged the S&P 500's 0.78% gain on the day. Elsewhere, the Dow gained 1.14%, while the tech-heavy ...

Recursion is hosting about 60 investors and analysts at its headquarters in Utah. It has generated tons of data with AI and robots, aiming to find a better way to make drugs.

Recursion announced the results from its Phase 2 SYCAMORE trial of REC-994, a treatment for Cerebral Cavernous Malformations (CCM), at the International Stroke Conference.